Escalating Morphine in Renal Failure: Twitching, Drowsiness, and Pain Still 7/10
Mr. D is 58 with castrate-resistant metastatic prostate cancer and bone metastases, stable on abiraterone, with an eGFR of 24 mL/min/1.73 m². He takes morphine extended-release 30 mg every 12 hours with immediate-release morphine 10 mg every 2 hours as needed, and has averaged 4–5 rescue doses a day for the past two weeks. Today he describes pain as 7/10 but is drowsy and intermittently difficult to rouse. His wife reports that he 'jumps' when she touches him and that his arms twitch constantly. He takes gabapentin 300 mg three times daily and senna with docusate. He is afebrile, has no new back pain, no focal weakness, and no confusion about who or where he is.
1. What do you think is happening, and what must be ruled out before you act on that impression?
Read the worked answer
Most likely opioid-induced neurotoxicity from morphine metabolite accumulation - but treat it as a hypothesis to be tested.
- Why this fits: morphine is renally cleared and its active metabolites (morphine-6- and morphine-3-glucuronide) accumulate at an eGFR of 24. The signature is exactly what is described - myoclonus, sedation, and pain that worsens rather than improves as the dose escalates (hyperalgesia). Dose escalation is the wrong response and makes it worse.
- Rule out the lethal look-alikes before you rotate: hypercalcemia of malignancy (check calcium and albumin), spinal cord compression (no new back pain or focal weakness, but a sensory level and bladder function still need checking), brain metastases or seizure activity, infection, dehydration and prerenal AKI, urinary retention, and a gabapentin contribution to the sedation.
- A key trap: treating the 7/10 pain with more morphine. If the pain is neurotoxic hyperalgesia, more opioid of the same class deepens the sedation and the twitching.
- Assess the whole pain mechanism: bone pain plus probable neuropathic components may need adjuvant therapy rather than escalating opioid.
- Nursing actions today: hold further morphine, stimulate and monitor, obtain calcium/renal panel/gabapentin level consideration, bladder scan, and contact the prescriber with a specific proposal rather than a report of symptoms.
2. Calculate an equianalgesic rotation and write the specific new orders.
Read the worked answer
Show your arithmetic; state the reduction; do not simply swap numbers.
- Current total daily dose: morphine ER 30 mg × 2 = 60 mg, plus 4.5 rescue doses × 10 mg = 45 mg → ~105 mg oral morphine/day.
- Choose the drug for the kidney, not just the number. Fentanyl is preferred in renal impairment because it has no active renally cleared metabolites. Hydromorphone is an alternative but its metabolites also accumulate at eGFR 24; oral oxycodone also accumulates. State this reasoning explicitly.
- Conversion: 105 mg oral morphine/day ≈ 40–50 mcg/h transdermal fentanyl in standard tables.
- Reduce for incomplete cross-tolerance: 25–50% reduction → start fentanyl 25 mcg/h every 72 hours. Rounding down is deliberate in an elderly, sedated patient with renal impairment.
- Overlap and breakthrough: the patch takes 12–24 hours to reach steady state, so continue a short-acting agent during the overlap and stop it once the patch is effective. Prescribe a non-morphine breakthrough (e.g., immediate-release hydromorphone 1 mg PO every 4 hours as needed, or transmucosal fentanyl per formulary) at roughly 10–15% of the daily dose.
- Stop the morphine completely and monitor for withdrawal (agitation, sweating, diarrhea, tachycardia) over 24–48 hours.
- Explicit orders: clonazepam 0.5 mg PO at bedtime or twice daily for myoclonus if the team agrees; continue gabapentin; continue bowel regimen (opioid + gabapentin); write the patch-change date and site rotation on the MAR.
3. What supportive and monitoring plan do you put in place, and how will you know it worked?
Read the worked answer
Define success before you change the drug, or you will not be able to tell neurotoxicity from progression.
- Monitoring over the next 24–72 hours: sedation score, respiratory rate, myoclonus frequency, pain score, and function (can he transfer, is he eating) at each shift; repeat calcium and renal panel; daily review of bowel function and bladder emptying.
- Hydration: address the prerenal component; avoid fluid overload in a patient with cancer and possible cardiac comorbidity - reassess after each bolus.
- Adjuvants for the mechanism: bone pain from metastases may respond better to NSAID (use cautiously at eGFR 24), radiation to a painful weight-bearing lesion, or a bisphosphonate/denosumab with calcium and vitamin D monitoring - not to more opioid. Neuropathic components justify gabapentin continuation.
- Non-pharmacologic: repositioning, heat, distraction, and a plan for the family so they are not left managing a sedated, twitching man at home without a number to call.
- What success looks like: at 48–72 hours, less myoclonus, improved alertness, pain at or below 4/10, and no withdrawal. If myoclonus and sedation persist after the rotation, look again for hypercalcemia or another cause rather than escalating the new opioid.
- Document the rotation rationale, including the equianalgesic math, so the next clinician does not 'correct' the dose upward.